×ž×“×™× ×”: טייוו×ן
שפה: ×¡×™× ×™×ª
מקור: 衛生ç¦åˆ©éƒ¨é£Ÿå“藥物管ç†ç½² (Ministry of Health and Welfare, Food And Drug Administration)
METFORMIN HCL (EQ TO METFORMIN HYDROCHLORIDE);;GLYBURIDE (EQ TO GLIBENCLAMIDE)
å°ç£é»˜å…‹è‚¡ä»½æœ‰é™å…¬å¸ å°åŒ—市內湖å€å ¤é ‚大é“2段89號6樓 (23526610)
A10BD02
膜衣éŒ
METFORMIN HCL (EQ TO METFORMIN HYDROCHLORIDE) (6820400710) MG; GLYBURIDE (EQ TO GLIBENCLAMIDE) (6820600700) MG
é‹ç®”ç›’è£
製 劑
é ˆç”±é†«å¸«è™•æ–¹ä½¿ç”¨
MERCK SANTE S.A.S CENTRE DE PRODUCTION SEMOY, 2 RUE DU PRESSOIR VERT, 45400 SEMOY, FRANCE FR
metformin and sulfonylureas
第二型糖尿病。
註銷日期: 2017/04/12; 註銷ç†ç”±: 自請註銷; 有效日期: 2018/08/02; 英文å“å: Glucovance 500mg/2.5mg Film-coated tablets
已註銷
2013-08-02
FR2579650 COMPOSITION Glucovance 500 mg/2.5 mg: Each file-coated tablet contains 500 mg metformin hydrochloride and 2.5 mg of glibenclamide as active ingredients. Glucovance 500 mg/ 5 mg: Each file-coated tablet contains 500 mg metformin hydrochloride and 5 mg of glibenclamide as active ingredients. APPEARANCE Glucovance 500 mg/2.5 mg: Orange capsule-shaped, biconvex, film-coated tablets with “2.5†engraved on one side. Glucovance 500 mg/ 5 mg: Yellow capsule-shaped, biconvex, film-coated tablets with “5†engraved on one side. INDICATIONS TREATMENT OF TYPE 2 DIABETES. Notes: Treatment of type 2 diabetic adult patients with any one of below situation. 1. When dietary management and exercise do not result in adequate glycaemic control. 2. When dietary management, exercise, and monotherapy with metformin or sulfonylurea do not result in adequate glycaemic control. 3. As replacement for previous combination therapy with metformin and sulfonylurea in patients whose glycaemia is stable and well controlled. DOSAGE AND ADMINISTRATION Oral. This drug is for adults use only. This drug should be prescribed by physicians. General As for all hypoglycaemic agents, the dosage should be adapted according to the individual metabolic response (glycaemia, HbA1c). Initial treatment: When dietary management and exercise do not result in adequate glycaemic control: The usual initial dose is 1 tablet of Glucovance 250 mg/1.25 mg daily or drugs with same compounds and equivalent doses. • When treatment failed by using monotherapy with metformin or a sulfonylurea: The usual initial dose is 1 tablet of Glucovance 500 mg/2.5 mg daily. • As replacement for previous combination therapy with metformin and glibenclamide: The recommended dose can be switched to equivalent Glucovance dose based on previous dose being taken. • As replacement for previous combination therapy with metformin and sulfonylurea: The recommended dose can be switched to 1 tablet of Glucovance 500 mg/2.5 mg daily based on previous dose being taken. Titration ×§×¨× ×ת המסמך השל×